[Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 Currently the Company is working diligently with the auditor to finish the audit and complete the 2014 10-K, and expect to file the 2014 Form 10-K within two weeks. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will] []
[Tianyin Pharmaceutical Provides Update on Filing of Form 10-K for Fiscal Year Ended June 30, 2014 Currently the Company is working diligently with the auditor to finish the audit and complete the 2014 10-K, and expect to file the 2014 Form 10-K within two weeks. Under NYSE MKT rules, until the Company files its Form 10-K, its common stock will] []
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 6 11 2 WuXi PharmaTech (Cayman) Inc.]
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 6 11 2 WuXi PharmaTech (Cayman) Inc.]
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[Form 6-K TABLE OF CONTENTS Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
[WuXi PharmaTech (Cayman) Inc. Form 6-K 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer]
[BEIJING, Aug. 27, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy. The Company's shareholders approved the following] []
[BEIJING, Aug. 27, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, today announced the results of the Company's 2014 Annual General Meeting of Shareholders held on Wednesday, August 27, 2014 in Beijing, PRC. The required quorum, a majority of the common shares outstanding, was voted by proxy. The Company's shareholders approved the following] []
[-- Conference call scheduled for Friday, August 15, 2014 at 8:00 AM ET -- BEIJING, Aug.14, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2014. Second Quarter 2014 Financial Highlights compared to the second quarter] []
